Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children

Trial Profile

Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2019

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals; Rifampicin
  • Indications HIV-1 infections; Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 17 May 2019 Planned End Date changed from 30 Sep 2019 to 30 Apr 2020.
    • 17 May 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Apr 2020.
    • 27 Jun 2018 Planned primary completion date changed from 1 May 2019 to 30 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top